Logo OnkologischesZentrum

DKG Zusatz DAH

Focus-Empfohlener-Arzt 2022

2022 Plakette Empfehlungsarzt2022 Onkologe Landkreis Donau RiesZum sechsten Mal in Folge wurde Prof. (SHB) Dr. med. Dirk Hempel im Mai 2022 mit seinen Tagesklinik in Donauwörth erneut von FOCUS-GESUNDHEIT ausgezeichnet.

Items starting with B




Encorafenib und Cetuximab bei Patienten mit metastasiertem, BRAFV600Emutiertem Kolorektalkarzinom.
Primäres Ziel ist die Bestimmung der Wirksamkeit der Zweifachblockade aus Encorafenib und Cetuximab. 
Multi-zentrische, multinationale, prospektive, longitudinale, nicht-interventionelle Studie in Deutschland und Österreich.


Encorafenib (BRAFTOVI®) plus Binimetinib (MEKTOVI®) bei Patienten mit fortgeschrittenem, nicht-resezierbarem oder metastasiertem, BRAFV600-mutiertem Melanom: eine multi-zentrische, multi-nationale, prospektive, nicht-interventionelle Längsschnittstudie in Deutschland, Österreich und der Schweiz

- Erste Real-World-Datenerhebung in Europa -



Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy


Study Population:
Participants with Stage II (high risk)/III CRC after resection (R0) and that are scheduled to receive AdCTx will be enrolled in this study.

Inclusion Criteria:

  • Must have given informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
  • Age ≥ 18 years old at time of signing the informed consent form.
  • Ability to comply with the study protocol, in the investigator's judgment.
  • Must have Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer per AJCC 2017 that has been surgically totally resected (R0 confirmed by pathology report). Stage II (high risk) colon cancer is defined as (any of): 
  •     T4
  •     Grade ≥ 3
  •     Clinical presentation with bowel obstruction or perforation
  •     Histological signs of vascular, lymphatic or perineural invasion
  •     < 12 nodes examined
  • Adequate tumor material in formalin-fixed paraffin embedded (FFPE) blocks or as sectioned tissue (only upon approval by sponsor) must be available, preferably from resection. The specimen should be submitted along with an associated pathology report. Multiple samples may be provided as available, but priority should be given to tissue with the highest tumor content and lowest necrotic area.
  • Intention to receive a standard of care adjuvant chemotherapy (AdCTx) within 8 weeks post-surgery, and be scheduled for at least 3 months of treatment according to the treating physician or investigator.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  • Adequate end-organ function.

Exclusion Criteria:

  • Induction of neoadjuvant systemic therapy prior to resection of CRC.
  • Prior systemic investigational therapy.
  • Positive serology for hepatitis B (unless immune due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy):
  •     Positive test for antibodies to hepatitis B core antigens (anti HBc) and
  •     Negative test for antibodies to hepatitis B surface antigens (anti HBs).
  • Active hepatitis C virus (HCV) infection; participants who have completed curative antiviral treatment with HCV viral load below the limit of quantification by polymerase chain reaction (PCR) are allowed.
  • Participant has a history of human immunodeficiency virus (HIV) antibody positivity, or tests positive for HIV at screening.
  • Residual tumor classification following surgery other than R0 (microscopic margin-negative resection).
  • Diagnosis with disease other than Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer per AJCC 2017 following surgery.
  • Participant has not started standard of care AdCTx within 8 weeks post-surgery.
  • Participant has received less than 3 months of AdCTx treatment.
  • Inadequate tumor material (either quality and quantity) to support circulating tumor DNA (ctDNA) analysis.


RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY / BREVITY-02 in Germany)

Brief Summary: The current study aims to provide validation results of RNA Disruption Assay (RDA) as a tumour response assessment tool that uses tumour core biopsies taken starting from 35 +/- 4 days after the initiation of neoadjuvant chemotherapy


Minimum Age: 18 Years

Sex: Female

Inclusion Criteria:

  • Women aged at least 18 years;
  • Patients must be able to provide informed consent and sign the informed consent form to participate in the RDA study before any study procedures starts;
  • Newly diagnosed clinical stage I, II or III breast cancer with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal;
  • Tumour size at least 1 cm in one dimension by clinical or radiographic exam (WHO criteria);
  • Must have histological confirmation of invasive breast cancer of any subtype or grade;
  • Patient is scheduled for neoadjuvant chemotherapy +/- antibodies and +/- other drugs according to Standard of Care;
  • Patient willing to have 2 research core needle biopsies (for RDA) taken at 2 collection timepoints during neoadjuvant chemotherapy treatment.

Exclusion Criteria:

  • Patient who has had prior local (i.e. surgery or radiotherapy) or systemic (i.e. endocrine or cytotoxic) therapy for the current breast cancer;
  • Participation in another interventional clinical trial with concurrent treatment with experimental drugs;
  • Stage IV breast cancer;
  • Bilateral, multifocal or multicentric breast tumour;
  • Prior malignant disease except curatively treated basalioma of the skin or pTis of the cervix uteri;
  • Concurrent pregnancy;
  • Breast feeding woman;
  • Concurrent medical, psychiatric or addictive disorders that may limit the ability to give informed consent or complete the trial;
  • Reasons indicating risk of poor compliance with study procedures;
  • Patient not able to consent

Internisten • Hämatologen • Onkologen • Palliativmedizin • Onkologische Tagesklinik

Onkologische Zentren
Prof. (SHB) Dr. med. Dirk Hempel